GLOBAL TRENDS, RISK FACTORS, AND CHALLENGES IN DRUG-RESISTANT TUBERCULOSIS: A SYSTEMATIC REVIEW OF ANTIMICROBIAL RESISTANCE PATTERNS AND DETERMINANTS

Ruth Chipampe  Kafwanka; Rogers  Chilyabanyama; Richard  Chirwa; Mubanga Lackson  Chipimo

doi:10.51168/sjhrafrica.v6i3.1591

Authors

Ruth Chipampe Kafwanka post Graduate Studies, University of Lusaka, Zambia.
Rogers Chilyabanyama Post Graduate Studies, University of Lusaka, Zambia.
Richard Chirwa Graduate School of Business, University of Zambia, Zambia
Mubanga Lackson Chipimo Post Graduate Studies, University of Lusaka, Zambia.

DOI:

https://doi.org/10.51168/sjhrafrica.v6i3.1591

Keywords:

Drug-resistant tuberculosis, Multidrug-Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis, Antimicrobial Resistance, Risk Factors, Treatment Challenges, Global Health

Abstract

Background

Drug-resistant tuberculosis (DR-TB) remains one of the greatest threats to global public health, with multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) posing significant challenges to TB control efforts. While scientific advancements have led to improved diagnostics and treatment options, the continued spread of resistant TB strains threatens to undo decades of progress. This systematic review synthesizes evidence on the global patterns of antimicrobial resistance (AMR) in TB, identifying key determinants, regional variations, and critical gaps in TB management.

Materials and Methods

A systematic review of published studies was conducted to examine the prevalence, risk factors, diagnostic and treatment challenges, and policy gaps contributing to AMR in TB. Studies were selected based on their focus on MDR-TB and XDR-TB, with a particular emphasis on regional differences, evolving resistance mechanisms, and healthcare system limitations.

Results

The review highlights significant regional variability in MDR-TB and XDR-TB prevalence, with the highest burden observed in sub-Saharan Africa, South Asia, and Eastern Europe. Increasing evidence suggests that primary MDR-TB transmission rather than treatment failure is driving resistance in high-burden regions, challenging traditional TB control strategies. Key risk factors include previous TB treatment, HIV co-infection, delayed diagnosis, and poor treatment adherence. Diagnostic challenges persist, with limited access to drug susceptibility testing (DST) and delayed MDR-TB detection contributing to prolonged infectious periods. Treatment barriers include adverse drug reactions, financial constraints, and the rising resistance to second-line drugs, particularly fluoroquinolones.

Conclusion

The growing burden of DR-TB underscores the urgent need for strengthened global TB control strategies, including expanded molecular diagnostics, enhanced adherence support, pharmacovigilance, and infection control measures. Without decisive action, MDR-TB and XDR-TB will continue to spread, increasing treatment failures and mortality rates. Urgent investment in TB research, new drug development, and healthcare infrastructure is critical to containing the global DR-TB epidemic.

References

Acharya, P., Bhattarai, N., Kunwar, B. R., Sharma, K. R., Khanal, V. K., & Yadav, B. K. (2024). Risk factors of multi-drug-resistant tuberculosis among tuberculosis patients in Province 3, Nepal: A case-control study. medRxiv, 2024-06. https://doi.org/10.1101/2024.06.16.24309002

Adewole, A. A., Gyamfi, S. P., & Eledi, J. M. (2024). Antimicrobial resistance and tuberculosis prevalence in Africa: A public health concern.

Alibrahim, A., Alqahtani, H., Thirunavukkarasu, A., & Qazi, I. (2024). Prevalence, patterns, and determinants of drug-resistant tuberculosis in Gulf Cooperation Council countries: An updated systematic review. PeerJ, 12, e18628. https://doi.org/10.7717/peerj.18628

Bagcchi, S. (2023). WHO's global tuberculosis report 2022. The Lancet Microbe, 4(1), e20. https://doi.org/10.1016/S2666-5247(22)00359-7

Bainomugisa, A., Pandey, S., Donnan, E., Simpson, G., Lavu, E., Hiasihri, S., McBryde, E. S., Moke, R., Vincent, S., Sintchenko, V., & Marais, B. J. (2019). Cross-border movement of highly drug-resistant Mycobacterium tuberculosis from Papua New Guinea to Australia through Torres Strait Protected Zone, 2010-2015. Emerging Infectious Diseases, 25(3), 406. https://doi.org/10.3201/eid2503.181003

Calligaro, G. L., Moodley, L., Symons, G., & Dheda, K. (2014). The medical and surgical treatment of drug-resistant tuberculosis. Journal of Thoracic Disease, 6(3), 186.

Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. J. H. W. (2019). Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: Wiley.

Che, Y., Li, X., Chen, T., Lu, Y., Sang, G., Gao, J., Gao, J., Liu, Z., He, T., & Chen, Y. (2024). Transmission dynamics of drug-resistant tuberculosis in Ningbo, China: An epidemiological and genomic analysis. Frontiers in Cellular and Infection Microbiology, 14, 1327477. https://doi.org/10.3389/fcimb.2024.1327477

Chekesa, B., Singh, H., Gonzalez-Juarbe, N., Vashee, S., Wiscovitch-Russo, R., Dupont, C. L., Girma, M., Kerro, O., Gumi, B., & Ameni, G. (2024). Whole-genome sequencing-based genetic diversity, transmission dynamics, and drug-resistant mutations in Mycobacterium tuberculosis isolated from extrapulmonary tuberculosis patients in western Ethiopia. Frontiers in Public Health, 12, 1399731. https://doi.org/10.3389/fpubh.2024.1399731

Diriba, G., Alemu, A., Yenew, B., Tola, H. H., Gamtesa, D. F., Mollalign, H., & Dangisso, M. H. (2023). Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Infectious Diseases, 132, 50-63. https://doi.org/10.1016/j.ijid.2023.04.392

Dlamini, T. C., Mkhize, B. T., Sydney, C., Maningi, N. E., & Malinga, L. A. (2023). Molecular investigations of Mycobacterium tuberculosis genotypes among baseline and follow-up strains circulating in four regions of Eswatini. BMC Infectious Diseases, 23(1), 566. https://doi.org/10.1186/s12879-023-08546-9

Duga, A. L. (2024). Patterns of adverse drug reactions in patients with drug-resistant tuberculosis in Eswatini: A retrospective cohort study (Doctoral dissertation, Université de Bordeaux).

Gao, W., Wang, W., Li, J., Gao, Y., Zhang, S., Lei, H., He, L., Li, T., & He, J. (2024). Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China. Antimicrobial Resistance & Infection Control, 13(1), 125. https://doi.org/10.1186/s13756-024-01482-6

Hlanze, H. (2024). The evolution of drug resistance in the different lineages of the Mycobacterium tuberculosis complex (Master's thesis, University of Pretoria, South Africa).

Joanna Briggs Institute. (2017). The Joanna Briggs Institute critical appraisal tools for use in JBI systematic reviews: Critical appraisal checklist for cohort studies.

Liebenberg, D., Gordhan, B. G., & Kana, B. D. (2022). Drug-resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Frontiers in Cellular and Infection Microbiology, 12, 943545. https://doi.org/10.3389/fcimb.2022.943545

Monde, N., Munyeme, M., Chongwe, G., Wensman, J. J., Zulu, M., Siziya, S., Tembo, R., Siame, K. K., Shambaba, O., & Malama, S. (2023). First and second-line anti-tuberculosis drug-resistance patterns in pulmonary tuberculosis patients in Zambia. Antibiotics, 12(1), 166. https://doi.org/10.3390/antibiotics12010166

Moreno Molina, M. Á. (2023). Functional and evolutionary genomics of antibiotic resistance in tuberculosis: From biology to global DR-TB control (Doctoral dissertation, Universitat Politècnica de València).

Mudenda, S., Mufwambi, W., & Mohamed, S. (2024). The burden of antimicrobial resistance in Zambia, a sub-Saharan African country: A one health review of the current situation, risk factors, and solutions. Pharmacology & Pharmacy, 15(12), 403-465. https://doi.org/10.4236/pp.2024.1512024

Mumena, D. K. (2023). Genotypic characterization of drug-resistant Mycobacterium tuberculosis among the new and previously treated tuberculosis cases from health facilities across seven provinces of Zambia (Doctoral dissertation, JKUAT-COHES).

Munn, Z., Barker, T. H., Moola, S., Tufanaru, C., Stern, C., McArthur, A., Stephenson, M., & Aromataris, E. (2020). Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. JBI Evidence Synthesis, 18(10), 2127-2133. https://doi.org/10.11124/JBISRIR-D-19-00099

Munn, Z., Stone, J. C., Aromataris, E., Klugar, M., Sears, K., Leonardi-Bee, J., & Barker, T. H. (2023). Assessing the risk of bias of quantitative analytical studies: Introducing the vision for critical appraisal within JBI systematic reviews. JBI Evidence Synthesis, 21(3), 467-471. https://doi.org/10.11124/JBIES-22-00434

Nangombe, V., Amkongo, M., Godman, B., & Kibuule, D. (2024). Drug-resistant tuberculosis treatment success predictors in Namibia. JAC-Antimicrobial Resistance, 6(6), dlae211. https://doi.org/10.1093/jacamr/dlae211

Nonghanphithak, D., Chaiprasert, A., Smithtikarn, S., Kamolwat, P., Pungrassami, P., Chongsuvivatwong, V., Mahasirimongkol, S., Reechaipichitkul, W., Leepiyasakulchai, C., Phelan, J. E., & Blair, D. (2021). Clusters of drug-resistant Mycobacterium tuberculosis detected by whole-genome sequence analysis of nationwide sample, Thailand, 2014-2017. Emerging Infectious Diseases, 27(3), 813. https://doi.org/10.3201/eid2703.204364

Nyasulu, P. S., Doumbia, C. O., Ngah, V., Togo, A. C. G., Diarra, B., & Chongwe, G. (2024). Multidrug-resistant tuberculosis: Latest opinions on epidemiology, rapid diagnosis, and management. Current Opinion in Pulmonary Medicine, 30(3), 217-228. https://doi.org/10.1097/MCP.0000000000001070

Reta, M. A., Tamene, B. A., Abate, B. B., Mensah, E., Maningi, N. E., & Fourie, P. B. (2022). Mycobacterium tuberculosis drug resistance in Ethiopia: An updated systematic review and meta-analysis. Tropical Medicine and Infectious Disease, 7(10), 300. https://doi.org/10.3390/tropicalmed7100300

Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., & Carpenter, J. R. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355. https://doi.org/10.1136/bmj.i4919

World Health Organization. (2021). Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. World Health Organization.

Wells, G. A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2021). The Newcastle Ottawa Scale. Ottawa Hospital Research Institute.